Abstract 289P
Background
Palliative chemotherapy is the standard of care for patients with advanced nasopharyngeal carcinoma. Radiotherapy may be offered for patients who responded to chemotherapy for local control. However, the dose and fractionation schedules used varies between oncologists.
Methods
An online survey via email was conducted for all practicing oncologists in public hospitals in Malaysia. The questionnaires were sent to 42 oncologists. The questionnaires gathered data on their practice in giving radiotherapy to patients with advanced nasopharyngeal carcinoma who responded to palliative chemotherapy,.
Results
33 oncologists responded to the questionnaire, which gave a response rate of 78.5%. Most oncologists (85%) will give radiotherapy if patients responded to palliative chemotherapy, and 90.9% will give radiotherapy alone without concurrent chemotherapy. The radiotherapy dose fractionation schedules vary among the oncologists, with 55Gy/20 fractions/4 weeks the commonest fractionation used (30.3%), followed by 40Gy/15 fractions/3 weeks (24.2%), and 9.1% choosing schedules such 30Gy/10 fractions/2 weeks, 45Gy/15 fractions/3 weeks, and 70Gy/35 fractions/7 weeks. The other fractionations used are 52Gy/13 fractions/2.5 weeks, 50Gy/25 fractions/5 weeks, 60Gy/25 fractions/5 weeks, 66Gy/33 fractions/6.5 weeks, and 60Gy/30 fractions/6 weeks. Most oncologists will prefer a fractionation schedules of 3-4 weeks duration (75.8%), with high enough dose to give a good local control and avoiding long treatment duration, as the radiotherapy is non-curative in nature.
Conclusions
There are currently no guidelines or consensus on the optimum radiotherapy dose fractionation schedules for this group of patients. The decision for the preferred dose-fractionation schedules have to take into consideration factors such as symptoms, disease extent and comorbidity. An optimum dose-fractionation schedule which does not prolong the treatment duration and giving the best local control is very much needed, especially in situations such as the current COVID-19 pandemic.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session